# Huaren Shengwu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huaren-shengwu

- Industry: Biotechnology
- Headquarters: Qingdao, China
- Website: www.huarenshengwu.com
- Total disclosed funding: $16M
- Latest round: Series A (Oct 25, 2021)
- Investors on record: 1

## About

Based in Qingdao, China and founded in 2012, Huarin Biotechnology (Qingdao) Co., Ltd., trading as Huaren Shengwu, is a biopharmaceutical company that provides biomacromolecule drugs. More than 80% of members of the core research team has master's degree. In 2018, the firm received the State High & Innovative Technology Companies Award. In 2022, the phase II clinical trial of Platelet-Derived Growth Factor (TPG) started. In December 2025,?Huaren Shengwu?raised HKD?674.18 million?in an IPO, selling?17.65 million shares?at?HKD 38.20 per share at HKEX, under the ticker "2396".
The company focuses on the research of biomacromolecule drugs such as protein products, nucleic acid-based medicine, and new cancer therapeutics which include growth factors, enzymes, mRNA vaccines, etc. The company sets up many technology platforms, such as yeast expression platform, mRNA platform, and nanocapsule delivery system. 
The company's revenue is generated by providing biomacromolecule drugs.

## Funding rounds

- Series A, Oct 25, 2021, $16M — CDH Investments

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A